A new collaboration between Baton Rouge-based Amedisys and Option Care Health Inc. in Illinois is piloting antibody infusions for coronavirus patients at nursing homes and long-term care facilities.
The pilot program — in coordination with the federal government's Operation Warp Speed — will expand access to infusion therapies to patients starting in Indianapolis and Valparaiso, Indiana, but is expected to expand to other markets.
The program will use both Bamlanivimab and Regeneron to treat coronavirus patients with mild to moderate symptoms by using the antibody therapies to reduce the chance of hospitalizations and worsening symptoms.
Home health provider Amedisys will oversee the care coordination for residents through clinical staff, while Option Care Health looks to leverage its pharmacy network to distribute Bamlanivimab.
“We have experience from being on the frontlines and caring for more than 12,500 COVID 19-positive patients,” said Paul Kusserow, chief executive officer of Amedisys. “We know how important innovative solutions are for caring for those who need our services the most, and this is exactly the type of partnerships in which Amedisys wants to be involved to help our country make it through this pandemic."